文献速递临床试验与 GCP基础与转化研究

冠状动脉旁路移植术中直接心脏冲击波治疗缺血性心肌病的安全性与有效性(CAST-HF试验):随机对照试验研究方案

Safety and efficacy of direct Cardiac Shockwave Therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-05-30

CAST-HF试验为前瞻性、随机对照、单盲、单中心研究,计划纳入80例LVEF≤40%的缺血性心肌病患者,在CABG术中随机1:1接受额外心脏冲击波治疗或假治疗。主要终点为治疗12个月后的主要心脏事件和左心室功能变化,旨在评估该辅助治疗的安全性及促心肌再生疗效。

要点

  • 心脏冲击波治疗通过促血管生成和减少纤维化瘢痕,在临床前研究中改善缺血心肌的左心室功能。
  • 该试验在CABG术中辅助应用心脏冲击波治疗,主要评估安全性和12个月左心室功能变化。
  • 若证实有效,可能成为首个临床可用的缺血心肌再生治疗策略。

核心结论

  • 该研究方案旨在评估CABG术中辅助心脏冲击波治疗缺血性心肌病的安全性和有效性,以促心肌再生并改善左心室功能。

研究设计与样本

  • 前瞻性、随机对照、单盲、单中心研究,计划纳入80例LVEF≤40%的缺血性心肌病患者。
  • 患者接受CABG手术后按1:1随机分为心脏冲击波治疗组(40例)和假治疗对照组(40例)。

关键数值与推荐

  • 纳入标准为左心室射血分数(LVEF)≤40%的缺血性心肌病患者。
  • 主要终点为治疗12个月后的主要心脏事件和左心室功能变化。
  • 次要终点包括6分钟步行试验距离、症状改善和生活质量评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary artery diseases (CAD) remains a severe socio-economic burden in the Western world. Coronary obstruction and subsequent myocardial ischemia result in progressive replacement of contractile myocardium with dysfunctional, fibrotic scar tissue. Post-infarctional remodeling is causal for the concomitant decline of left-ventricular function and the fatal syndrome of heart failure. Available neurohumoral treatment strategies aim at the improvement of symptoms. Despite extensive research, therapeutic options for myocardial regeneration, including (stem)-cell therapy, gene therapy, cellular reprogramming or tissue engineering, remain purely experimental. Thus, there is an urgent clinical need for novel treatment options for inducing myocardial regeneration and improving left-ventricular function in ischemic cardiomyopathy. Shockwave Therapy (SWT) is a well-established regenerative tool that is effective for the treatment of chronic tendonitis, long-bone non-union and wound-healing disorders. In preclinical trials, SWT regenerated ischemic myocardium via the induction of angiogenesis and the reduction of fibrotic scar tissue, resulting in improved left-ventricular function. METHODS/DESIGN: In this prospective, randomized controlled, single-blind, monocentric study, 80 patients with reduced left-ventricular ejection fraction (LVEF≤ 40%) are subjected to coronary-artery bypass-graft surgery (CABG) surgery and randomized in a 1:1 ratio to receive additional cardiac SWT (intervention group; 40 patients) or CABG surgery with sham treatment (control group; 40 patients). This study aims to evaluate (1) the safety and (2) the efficacy of cardiac SWT as adjunctive treatment during CABG surgery for the regeneration of ischemic myocardium. The primary endpoints of the study represent (1) major cardiac events and (2) changes in left-ventricular function 12 months after treatment. Secondary endpoints include 6-min Walk Test distance, improvement of symptoms and assessment of quality of life. DISCUSSION: This study aims to investigate the safety and efficacy of cardiac SWT during CABG surgery for myocardial regeneration. The induction of angiogenesis, decrease of fibrotic scar tissue formation and, thus, improvement of left-ventricular function could lead to improved quality of life and prognosis for patients with ischemic heart failure. Thus, it could become the first clinically available treatment strategy for the regeneration of ischemic myocardium alleviating the socio-economic burden of heart failure. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03859466. Registered on 1 March 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pölzl L, Nägele F, Graber M, et al. Safety and efficacy of direct Cardiac Shockwave Therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial. Trials. 2020. PMID: 32473644. doi:10.1186/s13063-020-04369-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。